1
|
Courdy C, Platteeuw L, Ducau C, De Araujo I, Boet E, Sahal A, Saland E, Edmond V, Tavitian S, Bertoli S, Cougoul P, Granat F, Poillet L, Marty C, Plo I, Sarry JE, Manenti S, Mansat-De Mas V, Joffre C. Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2 V617F myeloproliferative neoplasms. Blood Cancer J 2023; 13:106. [PMID: 37423955 DOI: 10.1038/s41408-023-00875-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2023] [Revised: 06/02/2023] [Accepted: 06/14/2023] [Indexed: 07/11/2023] Open
Abstract
The Janus kinase 2 (JAK2)-driven myeloproliferative neoplasms (MPNs) are chronic malignancies associated with high-risk complications and suboptimal responses to JAK inhibitors such as ruxolitinib. A better understanding of cellular changes induced by ruxolitinib is required to develop new combinatory therapies to improve treatment efficacy. Here, we demonstrate that ruxolitinib induced autophagy in JAK2V617F cell lines and primary MPN patient cells through the activation of protein phosphatase 2A (PP2A). Inhibition of autophagy or PP2A activity along with ruxolitinib treatment reduced proliferation and increased the death of JAK2V617F cells. Accordingly, proliferation and clonogenic potential of JAK2V617F-driven primary MPN patient cells, but not of normal hematopoietic cells, were markedly impaired by ruxolitinib treatment with autophagy or PP2A inhibitor. Finally, preventing ruxolitinib-induced autophagy with a novel potent autophagy inhibitor Lys05 improved leukemia burden reduction and significantly prolonged the mice's overall survival compared with ruxolitinib alone. This study demonstrates that PP2A-dependent autophagy mediated by JAK2 activity inhibition contributes to resistance to ruxolitinib. Altogether, our data support that targeting autophagy or its identified regulator PP2A could enhance sensitivity to ruxolitinib of JAK2V617F MPN cells and improve MPN patient care.
Collapse
Affiliation(s)
- Charly Courdy
- Centre de Recherches en Cancérologie de Toulouse (CRCT), INSERM UMR1037, CNRS UMR 5071, Université de Toulouse, Toulouse, France
- Equipe labellisée La Ligue contre le Cancer 2018, Toulouse, France
| | - Loïc Platteeuw
- Centre de Recherches en Cancérologie de Toulouse (CRCT), INSERM UMR1037, CNRS UMR 5071, Université de Toulouse, Toulouse, France
- Equipe labellisée La Ligue contre le Cancer 2018, Toulouse, France
| | - Charlotte Ducau
- Centre de Recherches en Cancérologie de Toulouse (CRCT), INSERM UMR1037, CNRS UMR 5071, Université de Toulouse, Toulouse, France
- Equipe labellisée La Ligue contre le Cancer 2018, Toulouse, France
| | - Isabelle De Araujo
- Centre de Recherches en Cancérologie de Toulouse (CRCT), INSERM UMR1037, CNRS UMR 5071, Université de Toulouse, Toulouse, France
- Equipe labellisée La Ligue contre le Cancer 2018, Toulouse, France
| | - Emeline Boet
- Centre de Recherches en Cancérologie de Toulouse (CRCT), INSERM UMR1037, CNRS UMR 5071, Université de Toulouse, Toulouse, France
- Equipe labellisée La Ligue contre le Cancer 2018, Toulouse, France
| | - Ambrine Sahal
- Centre de Recherches en Cancérologie de Toulouse (CRCT), INSERM UMR1037, CNRS UMR 5071, Université de Toulouse, Toulouse, France
- Equipe labellisée La Ligue contre le Cancer 2018, Toulouse, France
| | - Estelle Saland
- Centre de Recherches en Cancérologie de Toulouse (CRCT), INSERM UMR1037, CNRS UMR 5071, Université de Toulouse, Toulouse, France
- Equipe labellisée La Ligue contre le Cancer 2018, Toulouse, France
| | - Valérie Edmond
- INSERM UMR1287, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Suzanne Tavitian
- Service d'hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse III Paul Sabatier, Toulouse, France
| | - Sarah Bertoli
- Centre de Recherches en Cancérologie de Toulouse (CRCT), INSERM UMR1037, CNRS UMR 5071, Université de Toulouse, Toulouse, France
- Equipe labellisée La Ligue contre le Cancer 2018, Toulouse, France
- Service d'hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse III Paul Sabatier, Toulouse, France
| | - Pierre Cougoul
- Service de médecine interne, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France
| | - Fanny Granat
- Centre de Recherches en Cancérologie de Toulouse (CRCT), INSERM UMR1037, CNRS UMR 5071, Université de Toulouse, Toulouse, France
- Equipe labellisée La Ligue contre le Cancer 2018, Toulouse, France
| | - Laura Poillet
- Centre de Recherches en Cancérologie de Toulouse (CRCT), INSERM UMR1037, CNRS UMR 5071, Université de Toulouse, Toulouse, France
- Equipe labellisée La Ligue contre le Cancer 2018, Toulouse, France
| | - Caroline Marty
- INSERM UMR1287, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Isabelle Plo
- INSERM UMR1287, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Jean-Emmanuel Sarry
- Centre de Recherches en Cancérologie de Toulouse (CRCT), INSERM UMR1037, CNRS UMR 5071, Université de Toulouse, Toulouse, France
- Equipe labellisée La Ligue contre le Cancer 2018, Toulouse, France
| | - Stéphane Manenti
- Centre de Recherches en Cancérologie de Toulouse (CRCT), INSERM UMR1037, CNRS UMR 5071, Université de Toulouse, Toulouse, France
| | - Véronique Mansat-De Mas
- Centre de Recherches en Cancérologie de Toulouse (CRCT), INSERM UMR1037, CNRS UMR 5071, Université de Toulouse, Toulouse, France.
- Equipe labellisée La Ligue contre le Cancer 2018, Toulouse, France.
- Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse III Paul Sabatier, Toulouse, France.
| | - Carine Joffre
- Centre de Recherches en Cancérologie de Toulouse (CRCT), INSERM UMR1037, CNRS UMR 5071, Université de Toulouse, Toulouse, France.
- Equipe labellisée La Ligue contre le Cancer 2018, Toulouse, France.
| |
Collapse
|
2
|
Bosc C, Broin N, Fanjul M, Saland E, Farge T, Courdy C, Batut A, Masoud R, Larrue C, Skuli S, Espagnolle N, Pagès JC, Carrier A, Bost F, Bertrand-Michel J, Tamburini J, Récher C, Bertoli S, Mansat-De Mas V, Manenti S, Sarry JE, Joffre C. Autophagy regulates fatty acid availability for oxidative phosphorylation through mitochondria-endoplasmic reticulum contact sites. Nat Commun 2020; 11:4056. [PMID: 32792483 PMCID: PMC7426880 DOI: 10.1038/s41467-020-17882-2] [Citation(s) in RCA: 84] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2019] [Accepted: 07/22/2020] [Indexed: 12/14/2022] Open
Abstract
Autophagy has been associated with oncogenesis with one of its emerging key functions being its contribution to the metabolism of tumors. Therefore, deciphering the mechanisms of how autophagy supports tumor cell metabolism is essential. Here, we demonstrate that the inhibition of autophagy induces an accumulation of lipid droplets (LD) due to a decrease in fatty acid β-oxidation, that leads to a reduction of oxidative phosphorylation (OxPHOS) in acute myeloid leukemia (AML), but not in normal cells. Thus, the autophagic process participates in lipid catabolism that supports OxPHOS in AML cells. Interestingly, the inhibition of OxPHOS leads to LD accumulation with the concomitant inhibition of autophagy. Mechanistically, we show that the disruption of mitochondria–endoplasmic reticulum (ER) contact sites (MERCs) phenocopies OxPHOS inhibition. Altogether, our data establish that mitochondria, through the regulation of MERCs, controls autophagy that, in turn finely tunes lipid degradation to fuel OxPHOS supporting proliferation and growth in leukemia. How autophagy supports tumor cell metabolism is not fully clear. Here, the authors show that autophagy regulates lipid availability to support mitochondrial oxidative metabolism through mitochondria-endoplasmic reticulum contact sites, necessary for cell proliferation in AML.
Collapse
Affiliation(s)
- Claudie Bosc
- Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.,Equipe labellisée, La Ligue contre le Cancer, Toulouse, France
| | - Nicolas Broin
- Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.,Equipe labellisée, La Ligue contre le Cancer, Toulouse, France
| | - Marjorie Fanjul
- Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.,Equipe labellisée, La Ligue contre le Cancer, Toulouse, France
| | - Estelle Saland
- Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.,Equipe labellisée, La Ligue contre le Cancer, Toulouse, France
| | - Thomas Farge
- Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.,Equipe labellisée, La Ligue contre le Cancer, Toulouse, France
| | - Charly Courdy
- Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.,Equipe labellisée, La Ligue contre le Cancer, Toulouse, France
| | - Aurélie Batut
- MetaToul-MetaboHUB, National Infrastructure of Metabolomics and Fluxomics, Toulouse, F-31077, France
| | - Rawand Masoud
- Aix Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, Marseille, France
| | - Clément Larrue
- Translational Research Centre in Onco-hematology, Faculty of Medicine, University of Geneva, 1211, Geneva, Switzerland
| | - Sarah Skuli
- Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.,Equipe labellisée, La Ligue contre le Cancer, Toulouse, France.,Division of Hematology and Oncology, Hospital of The University of Pennsylvania, Philadelphia, PA, USA
| | - Nicolas Espagnolle
- STROMALab, Université de Toulouse, CNRS ERL5311, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France
| | - Jean-Christophe Pagès
- STROMALab, Université de Toulouse, CNRS ERL5311, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France
| | - Alice Carrier
- Aix Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, Marseille, France
| | - Frédéric Bost
- Inserm U1065, C3M, Team Cellular and Molecular Physiopathology of Obesity and Diabetes, Université Nice Côte d'Azur, Inserm, Nice, France
| | - Justine Bertrand-Michel
- MetaToul-MetaboHUB, National Infrastructure of Metabolomics and Fluxomics, Toulouse, F-31077, France
| | - Jérôme Tamburini
- Translational Research Centre in Onco-hematology, Faculty of Medicine, University of Geneva, 1211, Geneva, Switzerland.,Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, F-75014, Paris, France
| | - Christian Récher
- Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.,Equipe labellisée, La Ligue contre le Cancer, Toulouse, France.,Service d'hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France
| | - Sarah Bertoli
- Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.,Equipe labellisée, La Ligue contre le Cancer, Toulouse, France.,Service d'hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France
| | - Véronique Mansat-De Mas
- Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.,Equipe labellisée, La Ligue contre le Cancer, Toulouse, France.,Laboratoire d'Hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France
| | - Stéphane Manenti
- Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.,Equipe labellisée, La Ligue contre le Cancer, Toulouse, France
| | - Jean-Emmanuel Sarry
- Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France. .,Equipe labellisée, La Ligue contre le Cancer, Toulouse, France.
| | - Carine Joffre
- Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France. .,Equipe labellisée, La Ligue contre le Cancer, Toulouse, France.
| |
Collapse
|